Please login to the form below

Not currently logged in
Email:
Password:

Pomalidomide Celgene

This page shows the latest Pomalidomide Celgene news and features for those working in and with pharma, biotech and healthcare.

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

The 750-patrient ELOQUENT-1 trial showed that adding Empliciti (elotuzumab) to background treatment with BMS/Celgene’s Revlimid (lenalidomide) and dexamethasone didn’t extend the time patients with newly-diagnosed ... Celgene’s Pomalyst/Innovid

Latest news

  • FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma

    The study participants had on average received seven earlier lines of therapy, including an immuno-modulatory drug such as Celgene’s Revlimid (lenalidomide), a proteasome inhibitor such as Takeda’s Velcade ... The company is at the planning stages

  • GSK preps filings for BCMA-targeting multiple myeloma drug GSK preps filings for BCMA-targeting multiple myeloma drug

    It is the most advanced BCMA-targeting ADC in development, with candidates from AstraZeneca (MEDI2228) and Celgene/Sutro Biopharma (CC-99712) still in early-stage development. ... The company is also at the planning stages for a phase 3 trial of the drug

  • CHMP backs Bayer’s tumour-agnostic drug Vitrakvi CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

    Squibb got the go-ahead for Empliciti (elotuzumab) alongside Celgene’s Pomalyst (pomalidomide) and dexamethasone for relapsed/refractory multiple myeloma, based on the ELOQUENT-3 trial.

  • FDA verdict on Sanofi’s Darzalex rival is due in April 2020 FDA verdict on Sanofi’s Darzalex rival is due in April 2020

    prolong progression-free survival (PFS) when added to a standard myeloma regimen of Celgene’s Pomalyst/Imnovid (pomalidomide) and low-dose dexamethasone. ... Empliciti picked up an additional approval from the FDA as a third-line therapy for myeloma in

  • Janssen looks to expand Darzalex in Europe Janssen looks to expand Darzalex in Europe

    Regimen reduced risk of disease progression or death by 44%. Janssen is looking to broaden the use of its multiple myeloma blockbuster Darzalex, this time combining it with Celgene’s Revlimid ... Sanofi also has a promising CD38-targeting antibody for

More from news
Approximately 2 fully matching, plus 23 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...